| [1] |
O′Callaghan DS,Savale L,Yaici A,et al.Endothenlin receptor antagonists for the treatment of pulmonary arterial hypertension[J].Expert Opin Pharmacother,2011,12(10):1585-1596.
|
| [2] |
Song JM,Wen XA,Sun HB.Progress in pathogensis and therapeutic drugs of pulmonary arterial hypertension[J].J China Pharm Univ(中国药科大学学报),2013,44(1):1-10.
|
| [3] |
Frampton JE.Ambrisentan[J].Am J Cardiovasc Drugs,2011,11(4):215-226.
|
| [4] |
Condliffe R,Elliot CA,Hurdman J,et al.Ambrisentan therapy in pulmonary hypertension:clinical use and tolerability in a referral centre[J].Ther Adv Respir Dis,2014,8(3):71-77.
|
| [5] |
Riechers H,Albrecht HP,Amberg W,et al.Discovery and optimization of a novel class of orally active nonpeptidic endothelin-a receptor antagonists[J].J Med Chem,1996,39(11):2123-2128.
|
| [6] |
Riechers H, Muller TW, Klinge D, et al. New carboxylic acid derivatives,their preparation and their use:WO,9611914A1[P].1996-04-25.
|
| [7] |
Li XG.Study on the synthesis of ambrisentan[J].Appl Chem Ind(应用化工),2014,43(9):1675-1678.
|
| [8] |
Liu AX,Chen YF,Yu YK,et al.Improved synthesis of ambrisentan[J].Chem Wor(化学世界),2011,52(2):100-102.
|
| [9] |
Jansen R,Knopp M,Amberg W,et al.Structural similarity and its surprises:endothelin receptor antagonists process reseach and development report[J].Org Process Res Dev,2001,5(1):16-22.
|
| [10] |
Nestl BM,Glueck SM,Hall M,et al.Biocatalytic racemization of(hetero)aryl-aliphatic α-hydroxycarboxylic acids by Lactobacillus spp.proceeds via an oxidation-reduction sequence[J].Eur J Org Chem,2006,2006(20):4573-4577.
|
| [11] |
Peng XY,Li PJ,Shi Y.Synthesis of(+)-ambrisentan via chiral ketone-catalyzed asymmetric epoxidation[J].J Org Chem,2012,77(1):701-703.
|
下载:
